A Phase 4 interventional study of Adefovir dipivoxil and Lamivudine in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 12 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-02-02.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.
Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 13th largest by enrollment, is one of 5 that started in 2005, is one of 29 in phase 4, and was the 44th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:
IntegerBio · Sites in Hong Kong, Moldova, New Zealand and 1 more country
Ages 18–70 · Healthy volunteers
By country, each count listing its studies:
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 12 · Phase 4 29
First in 2002; this study’s year is marked. 5 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 255 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 114 across the 59 interventional studies. Of the 39 that completed or were terminated, 17 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 59 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
46 studies in Hepatitis B, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 45 finished, 25 (56%) have results posted.
Among the 46 studies in Hepatitis B, Chronic by Hoffmann-La Roche, this one is the 8th largest by enrollment of the 34 interventional ones that give a count, is one of 4 that started in 2005, is one of 16 in phase 4, and was the 38th registered.
Hoffmann-La Roche’s Hepatitis B, Chronic studies by the year they started, since 2002.
1 of the studies testing peginterferon alfa-2a in Hepatitis B, Chronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07389044IntegerBioA Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 46 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of peginterferon alfa-2a or ADV, in participants with lamivudine-resistant HBeAg-positive chronic hepatitis B. Participants will be randomized to receive either peginterferon alfa-2a for 48 weeks in combination with oral lamivudine for the first 12 weeks, or ADV for 72 weeks in combination with oral lamivudine for the first 12 weeks. The anticipated time on study treatment is 72 weeks, and the target sample size is 255 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ADV and lamivudine tablets at a dose of 10 mg orally QD for first 12 weeks followed by ADV for 60 weeks.
Drug: Adefovir dipivoxil · Drug: Lamivudine
Participants will receive peginterferon alfa-2a injection at a dose of 180 micrograms (mcg) once weekly (QW) and 100 milligrams (mg) lamivudine tablets orally once daily (QD) for first 12 weeks followed by peginterferon alfa-2a for 36 weeks.
Drug: Lamivudine · Drug: Peginterferon alfa-2a
ADV will be administered orally at a dose of 10 mg QD for 72 weeks.
Lamivudine tablets will be administered orally at a dose of 10 mg QD for 12 weeks.
Peginterferon alfa-2a injection will be administered at a dose of 180 mcg QW for 48 weeks.
Also known as: Pegasys
HBeAg seroconversion (defined as loss of HBeAg and presence of anti-HBe) at Week 72
Time frame: Week 72
Loss of HBeAg
Time frame: Week 48, and 72
Reduction in hepatitis B virus deoxyribonucleic acid (HBV DNA)
Time frame: Week 48, and 72
Alanine transaminase (ALT) normalization
Time frame: Week 48, and 72
Hepatitis B surface antigen (HBsAg) seroconversion
Time frame: Week 48, and 72
The record gives a start of Oct 2005, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2a